NMRA (Neumora Therapeutics) Moat Score: 3/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NMRA Neumora Therapeutics Inc NMRA
11 GF Score
Price $1.26
! 3 Warning Signs
View Full Analysis

What is Neumora Therapeutics Moat Score?

Neumora Therapeutics NMRA -4.58% 11 Moat Score is 3 as of Sep. 09, 2026. GuruFocus rates NMRA with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 1,384 Biotechnology companies, Neumora Therapeutics ranks better than 75.51% on this metric.

Neumora Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Neumora Therapeutics has No Moat: Neumora Therapeutics Inc has very weak competitive advantages. It lacks significant market leadership, network effects, and valuable intellectual property. The company does not exhibit strong brand strength or durable cost advantages, and its innovation capabilities are not yet impactful.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Neumora Therapeutics might have No Moat - Very weak/transient advantages.

Neumora Therapeutics  (NAS:NMRA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Neumora Therapeutics Moat Score Related Terms

NMRA vs ELDN, NAGE, CAMP: Moat Score Comparison

For the Biotechnology subindustry, Neumora Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neumora Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Neumora Therapeutics's Moat Score falls into.


NMRA
11GF Score
Neumora Therapeutics Inc NMRA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Neumora Therapeutics (NMRA) has a Moat Score of 3 as of Sep. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Neumora Therapeutics ranks #339 out of 1384 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Neumora Therapeutics' Moat Score too high?
Neumora Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Neumora Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Neumora Therapeutics ranks #339 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neumora Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Neumora Therapeutics' Moat Score compare to ELDN and NAGE?
According to the Biotechnology industry distribution chart, Neumora Therapeutics ranks #339 out of 1384 companies for Moat Score. This places Neumora Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Neumora Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neumora Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neumora Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neumora Therapeutics stock overvalued right now?
Neumora Therapeutics (NMRA) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Neumora Therapeutics' overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Neumora Therapeutics (NMRA), the current Moat Score is 3 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neumora Therapeutics Business Description

Address 260 Arsenal Place, Suite 1, Watertown, MA, USA, 02472
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
11GF Score

Get the complete analysis for NMRA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price